Profiling the protective B cell response to HCV

分析保护性 B 细胞对 HCV 的反应

基本信息

  • 批准号:
    9251760
  • 负责人:
  • 金额:
    $ 75.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2021-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Stanford Hepatitis C Cooperative Research Center will support an integrated research program focused on defining the immune correlates of protection against HCV in at-risk subjects that spontaneously clear their repeated infections. Cumulative evidence suggests that protective immunity against HCV includes both virus neutralizing (Vn) antibodies and cellular immunity. The availability of a specimen set of longitudinally collected samples from high-risk individuals followed from pre-infection to exposure followed by natural clearance or progression to chronic infection provides an unprecedented opportunity to characterize naturally-occurring immune protection. This Center will focus on the B cell response. Project 1 will analyze the specificity of the B cell responses employing high throughput isolation of Vn human monoclonal antibodies (HMAbs) by single cell cloning and by yeast display, with an emphasis on analyzing the response to the E1 glycoprotein. Functional and biochemical characterization of individual monoclonal antibodies will provide insights into the breadth of specificities of the Vn and non-Vn antibody responses, whether non-Vn antibodies interfere with Vn antibodies, and whether Vn antibodies elicited in subjects with chronic infections are more restrictive in their breadth of reactivity. Project 2 wil first explore the roles of virus-associated lipoproteins, HCV-receptor interactions, cell- to-cell transmission and non-Vn antiviral activity in modulating antibody-mediated functions; and will assess whether specific Vn or non-Vn HMAbs exhibit an antiviral effect through their Fc part by studying their ability to contribute to an antiviral effect through their interaction with Fc recepors and/or intracellular viral neutralization. Second, the project will determine the in vivo function f Vn and non-Vn HCV HMAbs in a human liver chimeric mouse model for acute HCV infection. The potency and breadth of protection of selected Vn HMAbs, single and in combination, and the ability of non-Vn HMAbs to interfere with this protection will be assessed in this small animal model of acute HCV infection. Collectively, the information gained from these studies will provide the basis for rational vaccine design, and provide much needed insights into the molecular specificities of antibodies that should be elicited by immunization.
描述(由申请人提供):斯坦福大学丙型肝炎合作研究中心将支持一项综合研究计划,重点是定义在自发清除重复感染的高危受试者中保护HCV的免疫相关性。累积的证据表明,针对HCV的保护性免疫包括病毒中和(Vn)抗体和细胞免疫。从高风险个体纵向采集的样本集的可用性,随后从感染前到暴露,然后自然清除或进展为慢性感染,为表征自然发生的免疫保护提供了前所未有的机会。该中心将重点关注B细胞反应。项目1将通过单细胞克隆和酵母展示高通量分离Vn人单克隆抗体(HMAb),分析B细胞应答的特异性,重点分析对E1糖蛋白的应答。单个单克隆抗体的功能和生物化学表征将提供对Vn和非Vn抗体应答的特异性的广度、非Vn抗体是否干扰Vn抗体、以及在具有慢性感染的受试者中引发的Vn抗体是否在其反应性的广度方面更具限制性的见解。项目2将首先探索病毒相关脂蛋白、HCV-受体相互作用、细胞间传递和非Vn抗病毒活性在调节抗体介导的功能中的作用;并将通过研究特异性Vn或非Vn HMAb通过其与Fc受体的相互作用和/或细胞内病毒中和作用促进抗病毒作用的能力来评估它们是否通过其Fc部分表现出抗病毒作用。第二,该项目将在急性HCV感染的人肝嵌合小鼠模型中确定Vn和非Vn HCV HMAb的体内功能。将在这种急性HCV感染的小动物模型中评估所选Vn HMAb(单独和组合)的保护效力和广度以及非Vn HMAb干扰这种保护的能力。总的来说,从这些研究中获得的信息将为合理的疫苗设计提供基础,并提供急需的对免疫接种应引起的抗体分子特异性的了解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven Foung其他文献

Steven Foung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven Foung', 18)}}的其他基金

A vaccine design to induce protective B and T cell immunity against hepatitis C virus
诱导针对丙型肝炎病毒的保护性 B 和 T 细胞免疫的疫苗设计
  • 批准号:
    10205546
  • 财政年份:
    2021
  • 资助金额:
    $ 75.22万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10797238
  • 财政年份:
    2021
  • 资助金额:
    $ 75.22万
  • 项目类别:
Structure-guided vaccine design of HCV E1E2 to induce broadly neutralizing antibodies (bNAbs)
HCV E1E2 的结构引导疫苗设计可诱导广泛中和抗体 (bNAb)
  • 批准号:
    10797240
  • 财政年份:
    2021
  • 资助金额:
    $ 75.22万
  • 项目类别:
Structure-guided vaccine design of HCV E1E2 to induce broadly neutralizing antibodies (bNAbs)
HCV E1E2 的结构引导疫苗设计可诱导广泛中和抗体 (bNAb)
  • 批准号:
    10205549
  • 财政年份:
    2021
  • 资助金额:
    $ 75.22万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10205547
  • 财政年份:
    2021
  • 资助金额:
    $ 75.22万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10409758
  • 财政年份:
    2021
  • 资助金额:
    $ 75.22万
  • 项目类别:
A vaccine design to induce protective B and T cell immunity against hepatitis C virus
诱导针对丙型肝炎病毒的保护性 B 和 T 细胞免疫的疫苗设计
  • 批准号:
    10409757
  • 财政年份:
    2021
  • 资助金额:
    $ 75.22万
  • 项目类别:
Structure-guided vaccine design of HCV E1E2 to induce broadly neutralizing antibodies (bNAbs)
HCV E1E2 的结构引导疫苗设计可诱导广泛中和抗体 (bNAb)
  • 批准号:
    10409760
  • 财政年份:
    2021
  • 资助金额:
    $ 75.22万
  • 项目类别:
A vaccine design to induce protective B and T cell immunity against hepatitis C virus
诱导针对丙型肝炎病毒的保护性 B 和 T 细胞免疫的疫苗设计
  • 批准号:
    10593174
  • 财政年份:
    2021
  • 资助金额:
    $ 75.22万
  • 项目类别:
Admin Core
管理核心
  • 批准号:
    9096394
  • 财政年份:
    2016
  • 资助金额:
    $ 75.22万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 75.22万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 75.22万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 75.22万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 75.22万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 75.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 75.22万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 75.22万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 75.22万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 75.22万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 75.22万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了